0IHV Stock Overview
Develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enzo Biochem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.04 |
| 52 Week High | US$1.57 |
| 52 Week Low | US$1.04 |
| Beta | 0.78 |
| 11 Month Change | -7.52% |
| 3 Month Change | -17.17% |
| 1 Year Change | -43.13% |
| 33 Year Change | -67.00% |
| 5 Year Change | n/a |
| Change since IPO | -86.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IHV | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -5.3% | -2.4% | -1.0% |
| 1Y | -43.1% | -25.0% | 7.3% |
Return vs Industry: 0IHV underperformed the UK Healthcare industry which returned -25% over the past year.
Return vs Market: 0IHV underperformed the UK Market which returned 7.3% over the past year.
Price Volatility
| 0IHV volatility | |
|---|---|
| 0IHV Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0IHV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0IHV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 185 | Kara Cannon | www.enzo.com |
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.
Enzo Biochem, Inc. Fundamentals Summary
| 0IHV fundamental statistics | |
|---|---|
| Market cap | US$56.09m |
| Earnings (TTM) | -US$17.55m |
| Revenue (TTM) | US$33.34m |
1.7x
P/S Ratio-3.2x
P/E RatioIs 0IHV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IHV income statement (TTM) | |
|---|---|
| Revenue | US$33.34m |
| Cost of Revenue | US$18.78m |
| Gross Profit | US$14.56m |
| Other Expenses | US$32.11m |
| Earnings | -US$17.55m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 43.66% |
| Net Profit Margin | -52.64% |
| Debt/Equity Ratio | 5.6% |
How did 0IHV perform over the long term?
See historical performance and comparison